Results Isolates were recovered from: urethra (36), endocervix (3) and conjunctiva (1). Results of MIC 50 and MIC 90 ($\mu\text{g/ml}$) were: PEN 0.5 and 4; TET: 1 and 32; CIP: 1 and 4; AZI: 0.25 and 0.5; CFX: 0.016 and 0.03; CRO: 0.008 and 0.016. Isolates with combined resistance to CIP-AZI-PEN, PEN-TET-CIP and CIP-TET-AZI were observed. Cephalosporin resistant Ng isolates was not observed although 2 isolates with decreased susceptibility to CFX (MIC 0.125 $\mu\text{g/ml}$) were found. The patient medical records were reviewed and no epidemiological relation was found among the patients with harbour strains with simultaneous resistance and clinical features. Patients were treated with CRO 500 mg IM plus AZI 1 g. The post treatment clinical controls were negative.

Conclusion The finding of Ng strains with decreased susceptibility to third generation cephalosporins is a warning signal. In addition to this, the presence of isolates with resistance to different classes of antibiotics, support the need to strength surveillance studies, evaluate treatment failures and improve prevention strategies to control of gonorrhoea in our population.

P3.224 PARTNER NOTIFICATION AND PARTNER TREATMENT FOR CHLAMYDIA: ATTITUDE AND PRACTICE OF GENERAL PRACTITIONERS IN THE NETHERLANDS

¹Van Den Broek Iv, ²Donker Ga, ³K Hek, ¹Van Benthem Bhb, ³Van Bergen Jeam, ⁴Götz Hm. ¹Centre for Infectious Diseases Control, National Institute for Public Health and The Environment, Bilthoven, The Netherlands; ²Nivel Primary Care Database, Sentinel Practices, Netherlands Institute for Health Services Research, Utrecht, The Netherlands; ³Department of General Practice, Academic Medical Centre and SOA AIDS Nederland, Amsterdam, The Netherlands; ⁴Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, The Netherlands

10.1136/sextrans-2017-053264.459

Introduction: *Chlamydia* prevalence remains high despite scaled-up control efforts. In the Netherlands, the majority of chlamydia patients are seen by general practitioners (GPs). Partner notification (PN) and partner treatment (PT) are addressed in GP guidelines but may not be fully covered in daily practice. As part of a larger research project into the potential of direct partner treatment for chlamydia (PICC-UP: Patient Initiated Contact treatment for Chlamydia), we investigated current practice and attitude of GPs towards PN/PT.

Methods Multiple data-sources were combined. First, we collected information on current practice via two short questionnaires around a national GP conference: a pre-conference survey (n=1411) and a handout one on location (n=271). Furthermore, quantitative data on (potential) PT were obtained from prescriptions in electronic patient data from 311 practices in the NIVEL Primary Care Database and from additional data on STI consultations in a subgroup of 45 sentinel practices. Finally, we obtained more insight into GPs' attitude towards PN/PT in a vignette study among GPs in the same network (n=268).

Results In the questionnaires, the large majority of GPs (>95%) indicated to discuss PN of current and ex-partner(s) with chlamydia patients. Usually, GPs leave further steps to the patients (83%); partners are rarely treated directly (4%), except when partners are registered in the same practice (16%). Of all prescriptions of Azithromycin linked to chlamydia episodes, 2% were double dosages, presumably for PT. At

STI consultations, the partners of 6/100 chlamydia patients were treated directly, either via partner prescription or double doses for the index patient. Test-results were communicated over the telephone in two thirds of chlamydia diagnoses, limiting the options for PN/PT. In the vignette study, the GPs' attitude appeared to be more open to PT than in current practice: 16%–20% of GPs indicated willingness to provide direct PT, depending on patient/partner profile; a larger group (24%–45%) would prescribe treatment for an (unseen) partner if the patient could notify him/her first. Advantages of direct PT given by the GPs were: better transmission control because of a higher chance to treat partners (at the same time), easier, cheaper. Disadvantages mentioned were: no chance to talk and give advice to partners, over-treatment, leading to resistance, impact on patient-GP relation and privacy. GPs were concerned about prescribing antibiotics for a patient they have not seen. The opinion of 10% of GPs was that direct PT should be possible for partners of all chlamydia patients, 21% thought for many, others only for some or by exception, while 11% was not in favour of it at all.

Conclusion At present, GPs in the Netherlands rarely treat partners of chlamydia cases directly, except for partners registered in the same practice. GPs may be open to options for direct PT, provided there are clear guidelines to arrange this legally and practically.

P3.225 NEISSERIA GONORRHOEAE BACTERIAL LOAD DIFFERS BETWEEN SAMPLE SITES

¹Van Der Veer Bmjw, ²Dukers-Muijers Nhtm, ²Hoebe Cjpa, ¹Van Alphen Lb, ¹Wolffs Pfg. ¹Maastricht University Medical Centre, Care and Public Health Research Institute, Maastricht, The Netherlands; ²Public Health Service South Limburg, Department of Sexual Health, Geleen, The Netherlands

10.1136/sextrans-2017-053264.460

Introduction To date, there is limited data on *Neisseria gonorrhoeae* (NG) bacterial load in relation to transmission and symptoms of NG infection. Also, extra-genital sites are not often tested apart from specific risk groups. This could lead to untreated infections that potentially facilitate transmission of NG. In this study we describe the NG bacterial load in relation to sample site, sexual orientation, and age.

Methods Routine diagnostics samples of the STI clinic of the South Limburg Public Health Service between 2012 and May 2016 were used. In this period, 1141 samples (883 male and 258 female) from 836 patients were NG positive, among which 237 urine samples, 130 genital swabs, 394 anorectal swabs, and 380 oropharyngeal swabs. Bacterial load was determined by interpolation of a standard curve using the COBAS 4800. Multiple linear regression was used to describe bacterial load in which sample site, sexual orientation, and age were the determinants.

Results In 471 of 629 (74.9%) patients with an extra-genital NG positive sample, only the extra-genital sample was positive, among these were 367 men who have sex (MSM) with men, 34 heterosexual men (HSM), and 70 women. Most patients were positive at a single sample site, 221 oropharyngeal (130 MSM, 32 HSM, and 59 women) and 165 anorectal respectively (154 MSM, 2 HSM, and 9 women). Sample site and age were significant determinants for load (both $p < 0.001$), in contrast to sexual orientation ($p = 0.096$). When

comparing sample sites oropharyngeal swabs have a significant lower load ($p < 0.001$), whereas urine samples have a significant higher load ($p < 0.001$). Genital and anorectal swabs loads do not differ ($p = 0.315$). Lower bacterial load appears to be correlated with older patients.

Conclusion NG bacterial load is for a large part driven by sample site. Oropharyngeal NG infections are often asymptomatic which could be related to a lower bacterial load. However, the role of the observed load differences in transmission and symptoms should be addressed in future studies.

P3.226 OROPHARYNGEAL TESTING AND POSITIVITY AT THE STI CLINIC IN THE PAST 5 YEARS; TESTING MORE AND FINDING EVEN MORE

Van Liere Gafs, Dukers-Muijters Nhtm, Hoebe Cjpa. *Public Health Service South Limburg, Medical Microbiology Maastricht University Medical Centre, Geleen, The Netherlands*

10.1136/sextrans-2017-053264.461

Introduction Oropharyngeal *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) are not routinely tested for in STI clinic attendees. Although oropharyngeal infections are often asymptomatic, they contribute to transmission in the population. Routine systematic oropharyngeal testing was implemented in men who have sex with men (MSM) in 2010, and on behavioural indication in heterosexuals, but it is unknown whether this was successful in practice. Moreover, data on oropharyngeal testing and CT/NG positivity in heterosexuals is limited.

Methods Men and women aged >16 years attending our STI-clinic between 2009–2015 were included ($n = 47317$). Specimens were tested using NAATs. Data were collected on demographics and sexual behaviour. Multivariable backward logistic regression analyses were used to test associations with oropharyngeal testing and oropharyngeal CT and NG. Tested determinants were age, sex, symptoms, number of sex partners and warned by (ex) partner.

Results Oropharyngeal testing in heterosexuals increased yearly from 13% in 2009 to 16% in 2015 (OR 1.3, 95% CI 1.2–1.3). In MSM, testing increased from 88% to 98% (OR 1.6, 95% CI 1.5–1.8). Oropharyngeal CT positivity varied between 1.0%–1.6% in women (54/4198), between 0%–1.3% in heterosexual men (13/2226) and between 0.8%–1.5% in MSM (79/8158), but was not associated with year of testing. Oropharyngeal NG positivity varied between 1.5%–3.4% in women (123/4201), between 0.6%–4.1% in heterosexual men (61/2226) and between 2.8%–6.4% in MSM (406/8156). Oropharyngeal NG positivity increased with year of testing in heterosexual men (OR 1.2, 95% CI 1.01–1.4) and MSM (OR 1.2 95% CI 1.1–1.2).

Conclusion Routine oropharyngeal testing in MSM was successfully implemented in practice. Oropharyngeal CT positivity remained stable after increased oropharyngeal testing in all groups, and in women also for oropharyngeal NG. In heterosexual men and MSM, increased oropharyngeal testing led to increased oropharyngeal NG positivity. This justifies routine oropharyngeal testing in MSM, and warrants careful monitoring in heterosexuals.

P3.227 HIGH SUBSTANCE USE AND RISK FOR STI IN YOUNG HETEROSEXUALS AND MSM

Van Liere Gafs, Hoebe Cjpa, Dukers-Muijters Nhtm. *Public Health Service South Limburg, Medical Microbiology Maastricht University Medical Centre, Geleen, The Netherlands*

10.1136/sextrans-2017-053264.462

Introduction Substance use to enhance sexual pleasure and performance is well known among men who have sex with men (MSM). Studies report a higher *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG) prevalence among MSM who use substance before or during sex. Limited data exist on substance use in relation to CT and NG prevalence among young heterosexuals.

Methods CT and NG tested men and women aged <25 years attending our STI-clinic between 2010–2015 were included ($n = 3526$). Specimens were tested using nucleic acid amplification tests. Data were collected on demographics, sexual behaviour, smoking, alcohol intake and drug use; marijuana, gamma hydroxy butyrate (GHB), ketamine, cocaine, heroin, speed, ecstasy and poppers. Univariable and multivariable backward logistic regression analyses were used to test associations between substance use and CT/NG. Tested determinants were age, symptoms, number of sex partners and warned by (ex) partner.

Results CT prevalence was 13.6% ($n = 300$) for women, 15.4% ($n = 153$) for heterosexual men and 10.6% ($n = 35$) for MSM. For NG this was 1.0% ($n = 23$), 1.4% ($n = 14$), and 15.8% ($n = 52$) respectively. Substance use before or during sex varied between 26%–40% for drugs, 44%–67% for alcohol and 51%–64% for cigarette smoking. Among drug users, 39%–45% used multiple drugs, most often marijuana (84%), ecstasy (81%) and cocaine (51%). In young heterosexuals, smoking was independently associated with CT in women (OR 1.3 95% CI 1.1–1.7), and ketamine use in men (OR 4.5, 95% CI 1.6–12.7). For MSM, GHB use was independently associated with CT (OR 3.8, 95% CI 1.2–12.2) and ketamine use with NG (OR 4.7, 95% CI 1.3–16.9).

Conclusion Substance use before or during sex was reported often among young heterosexuals and MSM, and led to greater CT and NG (for MSM) risk. Different substance use was associated with different STI in different risk groups, therefore targeted care is an imperative. Prevention in STI clinics should include discussing drug use before or during sex, also in heterosexual youngsters.

P3.228 STI PREVALENCE AMONG MALE VICTIMS OF A SEXUAL ASSAULT: DATA FROM 12 YEAR PERIOD, STI CLINIC AMSTERDAM, THE NETHERLANDS

L Van Rooijen, Van Kempen, A Fewerda, MF Schim Van Der Loeff, HJC De Vries. *Public Health Service (GGD) of Amsterdam, Amsterdam, The Netherlands*

10.1136/sextrans-2017-053264.463

Introduction Little is known about male sexual assault victims (SAV), frequency of health care seeking after such assaults and the prevalence of sexual transmitted infections (STI). The objective of this study was to assess the prevalence of STI among male SAV attending the STI clinic of Amsterdam, the Netherlands.

Methods In the electronic patient database, sexual assault (SA) is recorded as one of the reasons for visiting the clinic. We collected routine clinical data from the period 2005–2016.

Characteristics and STI screening results of SAV and non-victims (NV) were compared. Backward multivariable logistic regression analysis was conducted to assess whether SAV was associated with STI positivity (chlamydia, gonorrhoea, infectious syphilis, infectious hepatitis B, and/or HIV).

Results Between 2005 and 2016 194,954 STI consultations were performed with male clients and in 135 (0.07%) consultations SA was reported. In 92% of the assaults no condom was used. In 91% of cases the assailant was a male. Forensic examination was performed in 13% of the cases. Prior to the STI clinic consultation, in 19% an HIV test had been performed and 35% were vaccinated against hepatitis B. SAV were less often Dutch (54% vs. 63% in NV, $p=0.027$), the median age was 28 years (vs. 30 in NV, $p=0.20$), and 28% reported STI related complaints (vs. 34% in NV, $p=0.15$). In the 6 months preceding the STI clinic visit, 56% of the male victims reported homosexual contacts only (vs. 39% in NV, $p<0.001$). STI positivity was 12.6% in SAV and 18.4% in NV ($p=0.080$). In multivariable analysis being an SAV was associated with a lower risk of STI (OR 0.51; 95% CI 0.51–0.86).

Conclusion Over twelve years, 135 male clients reported an SA. The majority of the sexual assaults posed a risk to contract an STI (no condom use and male assailant). SAV had a significant lower risk to test STI positive than NV attending the STI clinic. As most victims were not tested for HIV, and did not receive a hepatitis B vaccination after the assault, STI clinics can play a key role in providing care to SAV including STI testing.

P3.229 STI PREVALENCE AND FOLLOW-UP AMONG FEMALE VICTIMS OF A SEXUAL ASSAULT TESTED AT THE STI CLINIC IN AMSTERDAM, THE NETHERLANDS

L Van Rooijen, Van Kempen, A Fewerda, MF Schim Van Der Loeff, HJC De Vries. *Public Health Service (GGD) of Amsterdam, Amsterdam, The Netherlands*

10.1136/sextrans-2017-053264.464

Introduction During a sexual assault (SA), female victims may become infected with sexual transmitted infections (STI). Because of possibly high infection rates and low percentage returning for treatment, several STI clinics provide empiric antimicrobial therapy at the first consultation. The objective of this study was to assess the STI prevalence and follow-up of female sexual assault victims (SAV) at the STI clinic of Amsterdam, the Netherlands.

Methods In the electronic patient database, SA is recorded as one of the reasons for visiting the clinic. We collected routine clinical data from the period 2005–2016. Characteristics and STI screening results of SAV and non-victims (NV) were compared. Backward multivariable logistic regression analysis was conducted to assess whether SAV was associated with STI positivity (chlamydia, gonorrhoea, infectious syphilis, infectious hepatitis B, and/or HIV).

Results Between 2005 and 2016 166,808 STI consultations were performed with female clients and in 1066 consultations SA was reported. In 96% of the assaults no condom was used. All the assailants were male. Forensic examination was performed in 22% of the cases. Prior to the STI clinic consultation, in 10% an HIV test had been performed, 27% were vaccinated for hepatitis B and in 11% a pregnancy test was performed. SAV were less often Dutch (60% vs. 68% in NV, $p<0.001$), the median age was 24 years (vs. 24 in NV,

$p=0.003$) and 34% reported STI related complaints (vs. 24% in NV, $p<0.001$). STI positivity was 11.7% in SAV and 11.8% in NV ($p=0.53$). In the multivariable analysis being an SAV was not associated with STI (OR 0.99; 95% CI 0.82–1.19). 91.3% of the SAV requiring antibiotics returned to the clinic.

Conclusion The STI positivity in female SAV was comparable to NV attending the STI clinic. The return rate for treatment was high and does not support empiric prophylactic antimicrobial therapy. As most victims were not tested for HIV, and did not receive a hepatitis B vaccination after the assault, STI clinics can play a key role in providing care to SAV including STI testing.

P3.230 DOUBLE TROUBLE: THE IMPACT OF LOW RISK PERCEPTION AND HIGH RISK SEXUAL BEHAVIOUR ON CHLAMYDIA TRANSMISSION

¹Van Wees Da, ¹C Den Daas, ²Kretzschmar Me, ¹JC Heijne. *¹National Institute for Public Health And The Environment (RIVM), Bilthoven, The Netherlands; ²Julius Centre For Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands*

10.1136/sextrans-2017-053264.465

Introduction Transmission of *Chlamydia trachomatis* (chlamydia) is influenced by both sexual behaviour and psychological determinants (i.e., risk perception). However, mathematical models describing chlamydia transmission often consider only sexual behaviour. We explored the influence of incorporating risk perception in a mathematical model that estimated the impact of different testing scenarios on chlamydia prevalence.

Methods We developed a pair compartmental model with a susceptible-infected-susceptible structure representing heterosexuals aged 16–26 years. Model parameters were informed by an online pilot study ($n=173$) on sexual behaviour, psychological determinants, and chlamydia (re-) infections and will be updated with data from an ongoing longitudinal cohort study. The model population was divided in two sexual risk behaviour groups (based on the number of partners in the last year) and further divided in two risk perception groups (based on perceived risk for chlamydia). We compared the impact of an overall testing uptake of 20% per year on population chlamydia prevalence with different testing scenarios: 1) differential uptake among sexual behaviour groups (higher uptake in high sexual behaviour group) and additionally 2) differential uptake among risk perception groups (higher uptake in high risk perception groups).

Results Respondents with high sexual risk behaviour (SB) and low risk perception (RP) had the highest mean number of partners (high SB/low RP=5.3, compared to high SB/high RP=5.0, low SB/high RP=1.3 and low SB/low RP=1.1, $p<0.001$), shortest mean duration of partnerships (high SB/low RP=153 days, compared to high SB/high RP=233, low SB/high RP=512 and low SB/low RP=607 days, $p<0.001$) and the highest percentage of self-reported chlamydia infections in the past year (high SB/low RP=22.2%, compared to high SB/high RP=14.3%, low SB/high RP=3.1% and low SB/low RP=0%, $p=0.02$). Models that did not consider differential testing uptake among risk perception groups overestimated the impact of testing on chlamydia prevalence. This effect was largest in the high sexual behaviour/low risk perception group.

Conclusion Mathematical models incorporating risk perception could improve the estimation of the impact of testing interventions on the prevalence of chlamydia in specific subgroups.